🔍

AARTIPHARM - Aarti Pharma

📊 NSE: AARTIPHARM 🏢 Pharmaceuticals - Indian - Bulk Drugs & Formln 📅 Last Updated: 12/13/2025 17:44

📢 Recent Corporate Announcements

Aarti Pharmalabs Q3 FY26: Revenue at ₹425 Cr, PAT at ₹44 Cr; Declares ₹1.5 Interim Dividend

🔴 NEGATIVE ⭐ 7/10

EARNINGS 📅 16 Feb 2026, 11:04 AM

Aarti Pharmalabs reported a decline in Q3 FY26 revenue to ₹425 crores from ₹471 crores YoY, primarily due to pricing pressure in the API segment and operational delays at the new Atali plant. Profit After Tax (PAT) fell significantly to ₹44 crores compared to ₹74 crores in the same period last year. Management noted that ₹49 crores of revenue was deferred as goods in transit, which impacted the quarter's PBT by ₹19 crores. Consequently, the company has revised its FY26 outlook, expecting EBITDA to be largely in line with the previous year with only marginal growth.

Revenue decreased 9.8% YoY to ₹425 crores, while PAT dropped to ₹44 crores from ₹74 crores.
Deferred revenue of ₹49 crores due to goods in transit impacted Q3 PBT by ₹19 crores, expected to be realized in Q4.
CDMO segment remains a growth driver with 59 active projects, 40 of which are in the commercial stage.
Atali plant Phase 1 (₹300 crore capitalized) faced stabilization hiccups, delaying some CDMO validation quantities to Q4.
Board declared an interim dividend of ₹1.5 per share despite the earnings contraction.

💡 Investors should monitor the stabilization of the Atali plant and the ramp-up of Xanthine expansion in FY27, as FY26 growth is expected to be muted. The stock may face near-term pressure until API margins stabilize and new capacities begin contributing to the bottom line.

Aarti Pharmalabs Clarifies Delay in SEBI Regulation 30 Disclosure

🟡 NEUTRAL ⭐ 3/10

REGULATORY 📅 13 Feb 2026, 02:51 PM

Aarti Pharmalabs Limited has issued a clarification to the BSE regarding a delay in a corporate announcement originally submitted on February 6, 2026. The company explained that the disclosure, which was required within 24 hours under SEBI Regulation 30, was missed because the responsible official was on leave from February 3 to February 5, 2026. The matter was addressed immediately upon the official's return to office. This is a procedural administrative update and does not impact the company's financial or operational standing.

Clarification pertains to a corporate announcement submitted on February 6, 2026, at 04:21 PM.
The delay occurred as the concerned official was on leave between February 3 and February 5, 2026.
The disclosure was required under Regulation 30 of SEBI (LODR) Regulations, 2015.
Company confirms the delay was inadvertent and has now been taken on record by the exchange.

💡 No action is required from investors as this is a routine administrative clarification regarding a minor compliance delay.

Aarti Pharmalabs Releases Q3 FY26 Earnings Conference Call Audio Recording

🟡 NEUTRAL ⭐ 3/10

EARNINGS 📅 10 Feb 2026, 10:32 PM

Aarti Pharmalabs Limited has officially released the audio recording of its earnings conference call for the third quarter and nine months ended December 31, 2025. The recording follows the company's recent announcement of its unaudited financial results for Q3 FY26. This disclosure is a routine regulatory requirement under SEBI (LODR) Regulations 2015 to ensure transparency for all shareholders. Investors can access the detailed management commentary and Q&A session via the company's website link provided in the filing.

Audio recording of the Q3 FY26 earnings call is now available for public access.
The call covers financial performance for the quarter and nine months ended December 31, 2025.
Recording link is hosted on the official company website at https://www.aartipharmalabs.com/q3-fy26.
Compliance filing made under Regulation 30 of the SEBI (LODR) Regulations 2015.
The update follows the initial investor call intimation dated February 02, 2026.

💡 Investors should listen to the recording to gain insights into management's guidance on margins and the progress of their pharmaceutical pipeline. It is a useful resource for understanding the qualitative factors behind the Q3 financial performance.

Aarti Pharmalabs Issues Corrigendum: Dividend Declared for FY 2025-26

🟡 NEUTRAL ⭐ 3/10

DIVIDEND 📅 10 Feb 2026, 01:47 PM

Aarti Pharmalabs Limited has issued a clarification regarding its dividend announcement dated February 09, 2026. The company noted a typographical error where the dividend was incorrectly attributed to Financial Year 2024-25. The corrigendum confirms that the dividend is actually declared for the Financial Year 2025-26. No other changes have been made to the record date or other terms of the dividend distribution.

Correction of typographical error in the dividend announcement dated February 09, 2026
Dividend pertains to Financial Year 2025-26 instead of the previously stated FY 2024-25
Confirmed that all other details in the original record date intimation remain unchanged

💡 No action is required from investors as this is a clerical correction; simply note the correct financial year for tax and accounting purposes.

Aarti Pharmalabs Q3 Standalone PAT Falls 40% YoY to ₹43.8 Cr; EBITDA Margin Stable at 24.2%

🔵 WATCH ⭐ 8/10

EARNINGS 📅 10 Feb 2026, 01:01 PM

Aarti Pharmalabs reported a 9.7% YoY decline in standalone revenue to ₹425.3 crore for Q3-FY26, while PAT dropped 40.4% YoY to ₹43.8 crore, impacted by higher depreciation and finance costs. Despite the YoY decline, the company showed a strong sequential recovery with EBITDA rising 39% QoQ and margins remaining resilient at 24.22%. The CDMO segment is a key growth driver with 30-40% growth projected for FY26, although ₹49 crore in revenue was deferred this quarter due to goods in transit. Major capacity expansions in Xanthine (to 9,000 MTPA) and the Atali greenfield site are nearing completion, positioning the company for future scale.

Standalone revenue for Q3-FY26 stood at ₹425.3 crore, down 9.7% YoY but up 1.9% QoQ.
EBITDA margins remained stable at 24.22% vs 24.42% YoY, despite pricing pressures in the API segment.
Xanthine capacity expansion from 5,000 MTPA to 9,000 MTPA is on track for completion by March 2026.
CDMO segment currently has 59 active projects with 21 customers, expecting 30-40% revenue growth in FY26.
Net Debt/Equity ratio remains low at 0.26x, supporting ongoing total capex plans of approximately ₹550 crore.

💡 Investors should monitor the successful ramp-up of the Atali greenfield site and the commissioning of the Xanthine expansion in Q4-FY26. While YoY earnings are soft, the sequential recovery and strong CDMO pipeline suggest long-term growth potential.

Aarti Pharmalabs Allots 10,457 Equity Shares Under PSOP 2023

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 09 Feb 2026, 08:35 PM

Aarti Pharmalabs Limited has allotted 10,457 equity shares to eligible employees following the exercise of stock options under the Aarti Pharma Performance Stock Option Plan 2023. The allotment was approved by the Nomination and Remuneration Committee on February 9, 2026. This move increases the company's paid-up equity share capital to Rs. 45.33 crore. The total number of outstanding shares now stands at 9,06,57,751, each with a face value of Rs. 5.

Allotment of 10,457 equity shares of face value Rs. 5 each under PSOP 2023
Paid-up equity capital increased from previous levels to Rs. 45,32,88,755
Total number of fully paid-up equity shares now stands at 9,06,57,751
New shares will rank pari-passu with existing equity shares in all respects

💡 No action is required as this is a routine ESOP allotment with negligible equity dilution of approximately 0.01%. Investors should focus on the company's upcoming quarterly performance and sector trends.

Aarti Pharmalabs Declares ₹1.5 Interim Dividend; Record Date Set for Feb 16, 2026

🟢 POSITIVE ⭐ 6/10

DIVIDEND 📅 09 Feb 2026, 08:27 PM

Aarti Pharmalabs Limited has announced an interim dividend of ₹1.5 per equity share for the financial year 2024-25, representing a 30% payout on the face value of ₹5. The decision was finalized during the Board of Directors meeting held on February 09, 2026. The company has designated February 16, 2026, as the record date to identify shareholders eligible for the payout. This move reflects the company's commitment to returning value to its shareholders through consistent payouts.

Interim dividend of ₹1.5 per equity share declared for FY 2024-25
Dividend payout is 30% of the face value of ₹5 per share
Record date for dividend eligibility is fixed as February 16, 2026
Board meeting for the declaration took place on February 09, 2026

💡 Investors interested in the dividend must ensure they hold the shares before the ex-dividend date, typically one working day prior to the February 16 record date. Long-term investors should view this as a positive sign of cash flow management.

Aarti Pharmalabs Q3 Net Profit at ₹47.96 Cr; Declares ₹1.50 Interim Dividend

🔵 WATCH ⭐ 8/10

EARNINGS 📅 09 Feb 2026, 08:15 PM

Aarti Pharmalabs reported a consolidated net profit of ₹47.96 crore for the quarter ended December 31, 2025, a decline from ₹73.99 crore in the corresponding quarter of the previous year. Consolidated revenue from operations stood at ₹274.11 crore, which was impacted by ₹49.35 crore of revenue being deferred to Q4 due to goods being in transit. The company has declared an interim dividend of ₹1.50 per share (30% of face value). An exceptional item of ₹2.79 crore was recorded due to provisions for new labour codes.

Consolidated Net Profit for Q3 FY26 stood at ₹47.96 crore, down 35% YoY from ₹73.99 crore.
Revenue from operations was ₹274.11 crore, with an additional ₹49.35 crore in-transit revenue deferred to Q4.
Declared an interim dividend of ₹1.50 per equity share with a record date of February 16, 2026.
Exceptional charge of ₹279.49 lakhs recognized for incremental provision under new labour codes.
Consolidated EPS for the quarter fell to ₹5.29 from ₹8.16 in the year-ago period.

💡 Investors should monitor the Q4 results closely to see if the deferred revenue of ₹49.35 crore translates into a strong recovery in profitability. While the dividend provides some support, the year-on-year decline in earnings suggests a cautious approach until margins stabilize.

Aarti Pharmalabs Declares ₹1.5 Interim Dividend; Q3 Net Profit Rises to ₹47.96 Crore

🟢 POSITIVE ⭐ 7/10

DIVIDEND 📅 09 Feb 2026, 08:08 PM

Aarti Pharmalabs has declared an interim dividend of ₹1.5 per equity share (30% of face value) for FY 2025-26, with the record date set for February 16, 2026. For the quarter ended December 31, 2025, the company reported a consolidated net profit of ₹47.96 crore, a significant increase from ₹27.92 crore in the previous quarter. Although consolidated revenue dipped sequentially to ₹273.37 crore, the company noted that ₹49.35 crore in revenue was deferred to Q4 due to goods being in-transit. An exceptional provision of ₹2.79 crore was also made for new labour code compliance.

Declared interim dividend of ₹1.5 per equity share (30% on face value of ₹5)
Consolidated Net Profit grew to ₹47.96 crore in Q3 FY26 from ₹27.92 crore in Q2 FY26
Revenue of ₹49.35 crore deferred to Q4 FY26 due to goods in-transit at quarter-end
Exceptional item of ₹2.79 crore provisioned for impact of new labour codes
Record date for dividend eligibility fixed as Monday, February 16, 2026

💡 Investors should benefit from the dividend payout and the strong bottom-line growth. The deferred revenue from in-transit goods suggests a potentially robust Q4, supporting a positive outlook for the stock.

Aarti Pharmalabs Receives Rs 31.15 Lakh GST Demand and Penalty

🟡 NEUTRAL ⭐ 3/10

REGULATORY 📅 06 Feb 2026, 04:31 PM

Aarti Pharmalabs Limited has received an order from the CGST and Central Excise authorities involving a total demand of Rs 31.15 lakhs. This demand includes tax, interest, and a specific penalty of Rs 2.60 lakhs for the financial years 2022-23 and 2023-24. The issue pertains to alleged excess availment of Input Tax Credit and incorrect tax liability declarations. The company has stated that this order will not have any material impact on its financial or operational activities.

Total demand of Rs 31,15,608 inclusive of tax, interest, and penalty
Specific penalty of Rs 2.60 lakhs imposed under Section 74 of the CGST Act
Discrepancies identified in GSTR-3B, GSTR-1, and GSTR-9 filings for FY23 and FY24
Company confirms no material impact on financials or operations

💡 No action is required as the penalty amount is negligible compared to the company's scale. Investors should treat this as a routine regulatory disclosure.

Aarti Pharmalabs Schedules Q3-FY26 Earnings Conference Call for February 10, 2026

🟡 NEUTRAL ⭐ 4/10

EARNINGS 📅 02 Feb 2026, 02:54 PM

Aarti Pharmalabs Limited has announced its earnings conference call to discuss the financial results for the third quarter and nine months ended December 31, 2025 (Q3-FY26). The call is scheduled for Tuesday, February 10, 2026, at 4:00 PM IST. Senior management, including the Chairman, Vice Chairperson & MD, and CFO, will be present to interact with analysts and investors. This routine disclosure follows SEBI LODR regulations and provides a platform for stakeholders to understand the company's recent performance and future outlook.

Earnings conference call scheduled for February 10, 2026, at 16:00 IST.
Management representation includes Chairman Rashesh Gogri and MD Hetal Gogri Gala.
The call will cover financial performance for Q3-FY26 and the 9-month period of FY26.
Universal dial-in numbers provided are +91 22 6280 1116 and +91 22 7115 8017.
Event coordinated by Dolat Capital Market Pvt. Ltd.

💡 Investors should track the Q3-FY26 results release prior to the call and listen for management commentary on margin sustainability and the API business outlook. This is a standard event to gain clarity on the company's growth trajectory and operational efficiency.

Aarti Pharmalabs Clarifies Recent Trading Volume Spurt as Market Driven

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 12 Jan 2026, 02:52 PM

Aarti Pharmalabs Limited has responded to a surveillance query from the National Stock Exchange regarding a significant increase in trading volume. The company clarified that it has consistently disclosed all material events required under SEBI Regulation 30. Management stated there is no undisclosed information or pending announcements that would impact the stock's price or volume behavior. The company maintains that the recent volume movement is entirely market-driven and not based on internal developments.

NSE issued a surveillance query on January 09, 2026, regarding high trading volumes
Company confirmed compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Management stated no undisclosed material information or pending announcements exist
Volume increase is categorized by the company as 'absolutely market driven'

💡 This is a routine regulatory clarification and does not indicate any change in company fundamentals. Investors should continue to monitor the stock based on its financial performance rather than speculative volume spikes.

Aarti Pharmalabs Files Routine SEBI Compliance Certificate for Q3 FY26

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 06 Jan 2026, 04:58 PM

Aarti Pharmalabs Limited has submitted its quarterly compliance certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations for the quarter ended December 31, 2025. The certificate, issued by the company's registrar MUFG Intime India Private Limited, confirms the processing of dematerialization requests. Notably, the registrar reported that there were zero requests received from shareholders for dematerialization during this specific quarter. This is a mandatory administrative filing required to ensure the integrity of the company's shareholding records.

Quarterly compliance certificate filed for the period ending December 31, 2025.
Registrar MUFG Intime India confirmed zero shareholder requests for dematerialization were received during the quarter.
The filing confirms adherence to SEBI (Depositories and Participants) Regulations, 2018.
Confirms that the register of members has been updated within prescribed timelines.

💡 No action is required as this is a standard regulatory disclosure with no impact on the company's financial performance or business operations.

Aarti Pharmalabs Appoints Dr. Rakeshwar Bandichhor as Chief Scientific Officer - R&D

🟢 POSITIVE ⭐ 6/10

MANAGEMENT 📅 01 Jan 2026, 05:09 PM

Aarti Pharmalabs has appointed Dr. Rakeshwar Bandichhor as Chief Scientific Officer for R&D and Senior Management Personnel, effective January 1, 2026. Dr. Bandichhor brings over 25 years of extensive experience in API-R&D and Process Chemistry to the company. He joins from Dr. Reddy's Laboratories and holds a Ph.D. with postdoctoral experience from prestigious institutions in Germany and the USA. This appointment is expected to strengthen the company's technical leadership and research capabilities in the pharmaceutical space.

Dr. Rakeshwar Bandichhor appointed as Chief Scientific Officer - R&D effective January 1, 2026
Brings 25 years of rich experience in API-R&D and Process Chemistry
Previously associated with industry major Dr. Reddy's Laboratories in Hyderabad
Holds a Ph.D. and completed three postdoctoral trainings at universities in Germany and the USA

💡 Investors should view this as a positive step towards enhancing the company's R&D and API development capabilities. Monitor for future announcements regarding new product pipelines or process improvements under the new leadership.

Aarti Pharmalabs to Close Trading Window from Jan 1, 2026 for Q3 Results

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 22 Dec 2025, 11:41 AM

Aarti Pharmalabs Limited has announced the closure of its trading window for all designated persons starting January 1, 2026. This routine regulatory measure is in compliance with SEBI (Prohibition of Insider Trading) Regulations for the upcoming financial results for the quarter ending December 31, 2025. The window will remain closed until 48 hours after the official declaration of the Q3 results. The company will announce the specific date for the board meeting to approve these results in due course.

Trading window closure commences on Thursday, January 1, 2026.
Closure is mandated for the review of financial results for the quarter ending December 31, 2025.
The window will reopen 48 hours after the financial results are publicly disclosed.
The restriction applies to all Designated Persons and Connected Persons as per SEBI regulations.

💡 This is a standard regulatory filing and does not require any immediate action from retail investors. Investors should look out for the upcoming announcement regarding the board meeting date to track the company's Q3 performance.

View All AARTIPHARM Announcements on Live Market Tracking →

💰 Financial Performance

Revenue Growth by Segment

Consolidated operational revenue for Q2 FY26 was INR 418.3 Cr, representing an 8.7% YoY decline from INR 458 Cr. Segmentally, Xanthine Derivatives performed better than the previous year, and CDMO-CMO sales were higher YoY. However, overall API sales were significantly lower than the previous year, contributing to the top-line contraction.

Geographic Revenue Split

Not specifically disclosed in available documents, though the company maintains a strong presence in international markets and established relationships with global clients.

Profitability Margins

Gross and EBITDA margins saw a sharp decline in Q2 FY26. Consolidated PAT for Q2 FY26 was INR 27.9 Cr, a 48.9% decrease from INR 54.6 Cr in Q2 FY25. PAT margin contracted by 525 bps to 6.67% from 11.92% YoY. Profitability was impacted by a Forex loss of INR 7.4 Cr and the accounting of WIP for large orders where invoicing only occurs upon final delivery.

EBITDA Margin

Consolidated EBITDA for Q2 FY26 stood at INR 74.7 Cr, down 20.3% YoY from INR 93.7 Cr. The EBITDA margin was 17.86%, a contraction of 260 bps from 20.46% in Q2 FY25. This was driven by higher operating expenses (INR 343.6 Cr) and a shift in manufacturing focus toward early-stage intermediates which occupy capacity without immediate profit recognition.

Capital Expenditure

The company is executing a total planned investment of INR 550 Cr. This includes a Greenfield project at Atali, Gujarat (INR 400 Cr) for Intermediates and CDMO/CMO with a 450 KL capacity, and a Brownfield expansion at Tarapur, Maharashtra (INR 150 Cr) to add 9,000 MTPA capacity for Xanthine Derivatives. Both are expected to ramp up/commission by Q4 FY26.

Credit Rating & Borrowing

CRISIL has assigned a 'Stable' outlook. The company maintains a strong financial risk profile with a gearing ratio of 0.14 and total outside liabilities to adjusted networth of 0.44 as of March 31, 2023. Interest coverage was healthy at 16.36 times for fiscal 2023.

⚙️ Operational Drivers

Raw Materials

Key raw materials include intermediates for APIs and Xanthine derivatives. Specific chemical names are not listed, but raw materials constitute a significant portion of the INR 343.6 Cr operating expenses in Q2 FY26.

Import Sources

More than 33% of raw materials are imported from international markets, making the company susceptible to global supply chain disruptions and currency fluctuations.

Key Suppliers

Not disclosed in available documents; however, the company maintains healthy relations with a diverse base of global suppliers.

Capacity Expansion

Current Xanthine Derivative capacity at Tarapur is 9,000 MTPA with nearly 100% utilization. Expansion will add another 9,000 MTPA by Q4 FY26. The Atali Greenfield site (Phase 1: 450 KL) is scalable up to 8-10x its initial capacity to support long-term CDMO growth.

Raw Material Costs

Operating expenses, primarily driven by raw materials, were INR 343.6 Cr in Q2 FY26. While expenses decreased 5.7% YoY, they rose 18.1% QoQ, impacting margins. The company has a limited ability to pass on sharp increases in input prices to customers.

Manufacturing Efficiency

Current Xanthine capacity utilization is at 100%. Efficiency is being optimized by transferring more intermediates to current sites to fill capacity while new blocks are qualified through audits.

📈 Strategic Growth

Expected Growth Rate

8-12%

Growth Strategy

Growth will be driven by the commissioning of the Atali Greenfield site (INR 400 Cr) which targets the high-growth CDMO/CMO segment and the Tarapur Brownfield expansion (INR 150 Cr) to capture a larger wallet share of the beverage market. The company is also focusing on deep backward integration (8-10 stages in-house) to improve value capture.

Products & Services

Xanthine Derivatives (Caffeine, Theophylline) sold to the beverage industry, Active Pharmaceutical Ingredients (APIs), and Intermediates, alongside CDMO-CMO services for global pharma players.

Brand Portfolio

Aarti Pharmalabs (formerly Aarti Organics Ltd).

New Products/Services

New product development is focused on the CDMO/CMO segment and expanded Xanthine derivatives, with the Atali site designed specifically as a growth engine for these new lines.

Market Expansion

Expansion is targeted at the beverage customer segment and the global CDMO market, utilizing the 80-acre Atali land bank which allows for 8-10x Phase 1 scaling.

Strategic Alliances

Ganesh Polychem Limited became a Joint Venture effective April 1, 2025, following an addendum to the Shareholding Agreement.

🌍 External Factors

Industry Trends

The industry is shifting toward integrated CDMO models. Aarti Pharmalabs is positioning itself by expanding intermediate capacity and offering 8-10 stage in-house manufacturing to provide certainty to global customers.

Competitive Landscape

Faces intense competition in the API and Intermediate business, which contributed to lower API sales in the most recent quarter.

Competitive Moat

The moat is built on deep backward integration, established long-term relationships with beverage giants, and a strong financial profile (0.14 gearing). These are sustainable due to the high capital intensity and regulatory hurdles of the API/Xanthine industry.

Macro Economic Sensitivity

Highly sensitive to global pharmaceutical demand and raw material pricing cycles. A decline in operating margins below 18% is flagged as a rating sensitivity factor.

Consumer Behavior

Growth in the beverage segment is a key driver for Xanthine derivatives, leading to the 100% utilization of current capacity.

Geopolitical Risks

Exposure to international trade regulations and supply chain risks from the 33% import dependency.

⚖️ Regulatory & Governance

Industry Regulations

Operations are subject to stringent pharmaceutical manufacturing standards and audits; the company recently underwent audits to qualify facilities for future manufacturing blocks.

Taxation Policy Impact

The effective tax expense for Q2 FY26 was INR 10.8 Cr, representing approximately 27.9% of PBT.

⚠️ Risk Analysis

Key Uncertainties

Key risks include the successful ramp-up of the INR 550 Cr capex projects by Q4 FY26 and the volatility of raw material prices which could keep margins below the 18% threshold.